Leerink Partnrs Brokers Increase Earnings Estimates for XENE

Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) - Stock analysts at Leerink Partnrs increased their Q1 2025 earnings per share (EPS) estimates for shares of Xenon Pharmaceuticals in a note issued to investors on Sunday, April 13th. Leerink Partnrs analyst M. Goodman now anticipates that the biopharmaceutical company will post earnings of ($0.91) per share for the quarter, up from their prior forecast of ($0.97). The consensus estimate for Xenon Pharmaceuticals' current full-year earnings is ($3.10) per share. Leerink Partnrs also issued estimates for Xenon Pharmaceuticals' Q2 2025 earnings at ($1.14) EPS, Q3 2025 earnings at ($1.23) EPS, Q4 2025 earnings at ($1.22) EPS, FY2025 earnings at ($4.50) EPS, FY2026 earnings at ($4.60) EPS, FY2027 earnings at ($3.85) EPS, FY2028 earnings at ($3.05) EPS and FY2029 earnings at $0.25 EPS.

Several other research firms have also recently weighed in on XENE. Deutsche Bank Aktiengesellschaft initiated coverage on Xenon Pharmaceuticals in a report on Tuesday, February 11th. They set a "buy" rating and a $67.00 price target for the company. The Goldman Sachs Group reduced their price target on shares of Xenon Pharmaceuticals from $60.00 to $52.00 and set a "buy" rating on the stock in a research report on Thursday. StockNews.com cut shares of Xenon Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Wednesday, April 16th. Royal Bank of Canada reiterated an "outperform" rating on shares of Xenon Pharmaceuticals in a research report on Friday, February 28th. Finally, William Blair restated an "outperform" rating on shares of Xenon Pharmaceuticals in a research report on Friday, February 28th. One research analyst has rated the stock with a sell rating and ten have given a buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $56.78.

Xenon Pharmaceuticals Stock Performance

Shares of XENE traded up $0.48 during midday trading on Wednesday, hitting $35.59. 166,468 shares of the company traded hands, compared to its average volume of 436,233. The stock has a market cap of $2.72 billion, a price-to-earnings ratio of -12.62 and a beta of 1.21. The firm has a 50 day moving average of $35.02 and a 200-day moving average of $38.79. Xenon Pharmaceuticals has a 52 week low of $26.74 and a 52 week high of $46.00.

Xenon Pharmaceuticals (NASDAQ:XENE - Get Free Report) last posted its quarterly earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.84) earnings per share for the quarter, topping the consensus estimate of ($0.89) by $0.05.

Insider Buying and Selling at Xenon Pharmaceuticals

In other Xenon Pharmaceuticals news, CEO Ian Mortimer sold 22,468 shares of the firm's stock in a transaction that occurred on Friday, January 24th. The shares were sold at an average price of $40.20, for a total transaction of $903,213.60. Following the completion of the transaction, the chief executive officer now directly owns 31,302 shares of the company's stock, valued at approximately $1,258,340.40. This trade represents a 41.79 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Company insiders own 5.52% of the company's stock.

Institutional Trading of Xenon Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Prudential Financial Inc. grew its position in Xenon Pharmaceuticals by 177.7% during the 4th quarter. Prudential Financial Inc. now owns 39,000 shares of the biopharmaceutical company's stock worth $1,529,000 after purchasing an additional 24,956 shares during the period. JPMorgan Chase & Co. grew its holdings in Xenon Pharmaceuticals by 1,263.2% during the third quarter. JPMorgan Chase & Co. now owns 976,783 shares of the biopharmaceutical company's stock worth $38,456,000 after acquiring an additional 905,129 shares during the period. Barclays PLC raised its position in Xenon Pharmaceuticals by 1,275.5% during the third quarter. Barclays PLC now owns 14,993 shares of the biopharmaceutical company's stock valued at $590,000 after acquiring an additional 13,903 shares in the last quarter. Assenagon Asset Management S.A. lifted its holdings in Xenon Pharmaceuticals by 12.4% in the fourth quarter. Assenagon Asset Management S.A. now owns 238,522 shares of the biopharmaceutical company's stock valued at $9,350,000 after acquiring an additional 26,235 shares during the period. Finally, State Street Corp grew its stake in shares of Xenon Pharmaceuticals by 13.2% during the 3rd quarter. State Street Corp now owns 279,513 shares of the biopharmaceutical company's stock worth $11,004,000 after purchasing an additional 32,701 shares during the period. Institutional investors and hedge funds own 95.45% of the company's stock.

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.